

LABORATORY, INSTRUMENTAL, AND CLINICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDREN DURING THE POST-COVID-19 PERIOD

Bobomuratov T. A.

Mallaev Sh. Sh.

Mukhtorov M. G.

Tashkent State Medical University

Abstract

Background. COVID-19 infection triggers a multisystem inflammatory response and negatively affects the course of autoimmune diseases. In children, autoimmune disorders such as systemic lupus erythematosus (SLE) may worsen or manifest with new clinical features after COVID-19.

Objective. To compare the clinical and laboratory characteristics of systemic lupus erythematosus in children who had COVID-19 with those of patients treated before the pandemic.

Materials and Methods. The study was conducted at the Republican Specialized Scientific and Practical Medical Center of Pediatrics. Twenty-one patients with SLE who had recovered from COVID-19 (Group 1, prospective) were compared with forty-two SLE patients treated before the pandemic (Group 2, retrospective). Clinical, laboratory, and instrumental features were evaluated.

Results. In Group 1, leukocyte counts were increased ($5.2 \pm 0.5 \times 10^9/L$ vs. $4.1 \pm 0.4 \times 10^9/L$; $p < 0.05$), ESR was elevated (22.5 ± 2.2 mm/h; $p < 0.05$), and CRP levels were higher (14.5 ± 3.4 mg/L; $p \leq 0.05$). Platelet counts were decreased ($180.2 \pm 10.2 \times 10^9/L$ vs. $211.3 \pm 11.2 \times 10^9/L$; $p < 0.05$). Ultrasound examination revealed a higher frequency of reactive hepatitis (57.1%) and cholecystitis (57.1%).

Conclusion. Post-COVID-19 systemic lupus erythematosus in children is characterized by enhanced inflammatory activity, hematologic imbalance, and hepatobiliary system involvement. These findings underscore the need for individualized rehabilitation strategies and immunomodulatory monitoring.

Keywords: COVID-19, systemic lupus erythematosus, inflammation, CRP, ESR, reactive hepatitis, cholecystitis, post-COVID syndrome.

Introduction

COVID-19 infection (SARS-CoV-2) is a multisystem disease that leads to endothelial dysfunction and immune dysregulation. By binding to ACE-2 receptors, the virus enters host cells, triggering systemic inflammation and potentially developing multisystem inflammatory syndrome in children (MIS-C).

In pediatric patients with autoimmune diseases, particularly systemic lupus erythematosus (SLE), these inflammatory mechanisms may intensify disease activity. According to data from Johns Hopkins University, children account for approximately

8% of all COVID-19 cases. Therefore, assessing the post-COVID course of SLE in children is both clinically and scientifically significant.

Materials and Methods

The study was conducted at the Department of Cardioreumatology, Republican Specialized Scientific and Practical Medical Center of Pediatrics.

Study design: Mixed — prospective and retrospective.

Participants:

- **Group 1:** 21 children diagnosed with SLE after recovering from COVID-19;
- **Group 2:** 42 children diagnosed and treated for SLE before the pandemic.

Parameters evaluated:

- **Laboratory:** hemoglobin, erythrocytes, leukocytes, platelets, ESR, CRP, total protein, LDH.
- **Instrumental:** liver and biliary system assessment via ultrasonography, including reactive hepatitis, pancreatitis, and cholecystitis.
- **Clinical:** general asthenic symptoms, joint pain, and neurovegetative complaints.

Statistical analysis: Mean values were presented as mean $\pm$ standard error (SE). Intergroup differences were assessed using Student's t-test, with significance set at $p \leq 0.05$.

Results

Table 1. Laboratory parameters in the study groups

Parameters	1 group	2 group	p
Hemoglobin, g/L	105,5 $\pm$ 2,5	102,9 $\pm$ 3,5	
Erythrocytes	3,8 $\pm$ 0,4	4,1 $\pm$ 0,3	
Leukocytes, $\times 10^9$ /L	5,2 $\pm$ 0,5	4,1 $\pm$ 0,4	< 0,05
Platelets	180,2 $\pm$ 10,2	211,3 $\pm$ 11,2	< 0,05
ESR, mm/h	22,5 $\pm$ 2,2	14,9 $\pm$ 2,7	< 0,05
C-reactive protein	14,5 $\pm$ 3,4	10,4 $\pm$ 3,2	$\leq$ 0,05
Total protein, g/L	61,6 $\pm$ 12,4	63,8 $\pm$ 11,9	
LDH	305,4 $\pm$ 33,6	309,1 $\pm$ 30,7	

According to the data presented in Table 1:

- Leukocyte count was higher in Group 1 ($5.2 \pm 0.5 \times 10^9$ /L) compared to Group 2 ($4.1 \pm 0.4 \times 10^9$ /L; $p < 0.05$);
- Platelet count was reduced (180.2 ± 10.2 vs. 211.3 ± 11.2 ; $p < 0.05$);

- ESR and CRP levels were significantly elevated (22.5 ± 2.2 mm/h; 14.5 ± 3.4 mg/L; $p \leq 0.05$);
- No significant differences were observed in LDH levels.

Table 2. Ultrasound findings in the study groups (%)

Findings	I group	II group
Reactive pancreatitis	14,3	14,3
Intestinal pneumatosis	14,3	14,3
Cholecystitis	57,1	14,3
Reactive hepatitis	57,1	28,6

According to the ultrasound findings:

- Reactive hepatitis was detected in 57.1% of patients in Group 1 (compared to 28.6% in Group 2);
- Cholecystitis was identified in 57.1% (vs. 14.3% in Group 2);
- Reactive pancreatitis and intestinal pneumatosis were recorded in approximately 14.3% of cases.

These changes indicate an intensification of autoimmune processes in the post-COVID-19 period.




Figure 1. Main complaints of patients in the study groups (%)




Figure 2. Additional complaints of patients in the study groups (%)

Patients with juvenile rheumatoid arthritis experienced a significant increase in complaints such as dizziness, memory impairment, cardiac pain, constipation, irritability, and nasal bleeding following COVID-19 infection.

Discussion

The obtained data confirm that COVID-19 infection may aggravate the course of systemic lupus erythematosus (SLE) in children. SARS-CoV-2 induces endothelial injury and cytokine storm, which activate autoimmune mechanisms.

In our study, elevated leukocyte counts, ESR, and CRP levels indicate intensified inflammatory activity. Thrombocytopenia is likely associated with autoimmune hematologic reactions.

The ultrasound findings of reactive hepatitis and cholecystitis further demonstrate immunologically mediated hepatic and biliary system involvement.

These results are consistent with the findings of Feldstein et al. (2020) and Whittaker et al. (2020), who documented multisystem inflammatory responses in children after COVID-19.

Conclusion

1. Children with systemic lupus erythematosus demonstrated increased inflammatory markers (ESR, CRP, leukocytes) and decreased platelet count in the post-COVID-19 period.

2. Reactive hepatitis and cholecystitis were significantly more frequent on ultrasound examination.
3. Among clinical symptoms, asthenic and neurovegetative manifestations predominated.
4. Immunometabolic monitoring and individualized rehabilitation are essential for children with systemic lupus erythematosus in the post-COVID-19 period.

References

1. Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., ... & Randolph, A. G. (2020). Multisystem inflammatory syndrome in US children and adolescents. *New England Journal of Medicine*, 383(4), 334-346.
2. Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C. E., Shah, P., ... & Levin, M. (2020). Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *Jama*, 324(3), 259-269.
3. Zimmermann, P. & Curtis, N. Coronavirus infections in children including COVID-19. An overview of the epidemiology, clinical features, diagnosis, treatment, and prevention options in children. *Pediatr. Infect. Dis. J.* 39, 355–368 (2020)
4. CDC COVID-19 Response Team. COVID-19 in children in the United States—February, 12–April 2, 2020. *MMWR* 69, 422–426 (2020)
5. Yan R, Zhang Y, Li Y. et al. Structural basis for the recognition of the SARS-Cov-2 by full length human ACE-2. *Science*. 2020
6. Lukassen S, Chua RL, Trefzer T. et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches (preprint); bioRxiv. 2020
7. Muxtorov, M. G., and R. T. Yunusova. "BOLALARDA COVID-19 DAN KEYINGI DAVRDA BIRIKTIRUVCHI TO 'QIMANING TIZIMLI KASALLIKLARINING LABORATOR VA KLINIK XUSUSIYATLARI." *Журнал академических исследований нового Узбекистана* 1.6 (2024): 33-35.
8. Muxtorov, Maqsud. "BIRIKTIRUVCHI TO 'QIMANING TIZIMLI KASALLIKLARI BOR BOLALARDA COVID-19 NING UCHRASH CHASTOTASI." *Theoretical aspects in the formation of pedagogical sciences* 3.10 (2024): 149-151.
9. Bobomuratov, T. A., Sh, M. S., SB, F. N. E., & Muxtorov, M. G. (2024). SHIFOXONADAN TASHQARI ZOTILJAM BILAN KASALLANGAN BOLALARDA GEMOSTAZ TIZIMINING OZGARISHLARIDA GEN POLIMORFIZMINING ROLI. *TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI* Maxsus son: 168-171.
10. Mukhtorov, Mallaev Sh Sh Egamberdiev SB. "WAY TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS WITH GENETIC ENGINEERED BIOLOGICAL DRUGS." *Web of Scientist: International Scientific Research Journal*. Volume 5, Issue 11, November - (2024): 28-37.
11. Бобомуратов, Т. А., Маллаев, Ш. Ш., Файзиёв, Н. Н., Эгамбердиев, С. Б., & Мухторов, М. Г. (2024). РОЛЬ ГЕНЕТИЧЕСКОГО ПОЛИМОРФИЗМА PAI-1 В

- ТЯЖЕЛОМ ТЕЧЕНИИ ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИИ. TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son: 172-174.
12. Маллаев, Ш. Ш., Файзиев, Н. Н., Эгамбердиев, С. Б., & Мухторов, М. Г. (2024). ЭФФЕКТИВНОСТЬ ГЕННО-ИНЖЕНЕРНЫХ БИОПРЕПАРАТОВ В ЛЕЧЕНИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА У ДЕТЕЙ. TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son: 69-72.
 13. Mukhtorov, Mallayev Sh Sh Egamberdiev SB. "THE ROLE OF GENE POLYMORPHISM IN THE DEVELOPMENT OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN." British Journal of Global Ecology and Sustainable Development. Volume-33, October- (2024): 40-45.
 14. МУХТОРОВ, М. (2019). СОВРЕМЕННЫЕ ПРИНЦИПЫ ТЕРАПЕВТИЧЕСКОЙ ТАКТИКИ ПРИ ЮВЕНИЛЬНОМ РЕВМАТОИДНОМ АРТРИТЕ У ДЕТЕЙ. In Молодежь, наука, медицина (pp. 170-170).
 15. Sh, M. S. (2025). BOLALARDA COVID-19 DAN KEYINGI DAVRDA YUVENIL IDIOPATIK ARTRITNING INSTRUMENTAL, LABORATOR VA KLINIK XUSUSIYATLARI. Лучшие интеллектуальные исследования, 56(2), 175-184.
 16. Bobomuratov, T. A., Sh, M. S., & Mukhtorov, M. G. (2025). INSTRUMENTAL, LABORATORY, AND CLINICAL FEATURES OF JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN DURING THE POST-COVID-19 PERIOD. Modern education and development, 37(4), 73-82.
 17. Маллаев, Ш. Ш., Файзиев, Н. Н., & Мухторов, М. Г. (2024). ОПТИМИЗАЦИЯ ЛЕЧЕНИЯ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА БИОЛОГИЧЕСКИМИ ПРЕПАРАТАМИ. TOSHKENT TIBBIYOT AKADEMIYASI AXBOROTNOMASI Maxsus son: (2024): 48-51.
 18. Mallaev Sh.Sh, Bobomuratov T.A, Fayziev N.N., Sultanova N.S., Dinmukhammadieva D.R. Genetic Aspects of Juvenile Rheumatoid Arthritis. ISSN (E): 2795 – 7624 VOLUME 10 | JULY 2022. 1-5.
 19. Sh.Sh Mallaev, T.A Bobomuratov, N.S.Sultanova, G.A.Yusupova, A.A.Hoshimov.// Clinical characteristics and prediction of the outcome of juvenile rheumatoid arthritis in chronotherapy// Chin J Ind Hyg Occup Dis: Vol.39 (No.7). pp. 135-140.
 20. Ш.Ш Маллаев, А.В Алимов Сравнительная эффективность традиционной терапии и хронотерапии в лечении ювенильного ревматоидного артрита. // Новый день в медицине – 2020. – Т .1. №1 – С . 258-262.
 21. Ш.Ш Маллаев, А.В Алимов. Клиническое течение ювенильного ревматоидного артрита и его оптимизация лечения // журнал «Педиатрия» №2 Ташкент 2020. С. 200-203.
 22. Маллаев Ш.Ш., Алимов А.В. Clinical course of juvenile rheumatoid arthritis and its treatment optimization // Тиббиётда янги кун. – 2020. - №4 (32). – С. 68 -71. (14.00.00. - №22).
 23. Mallaev Sh.Sh., Alimov A.V. Clinic - laboratory manifestation of juvenile rheumatoid arthritis // Evroaziyskiy vestnik pediatrii. – 2020. - № 3 – P. 56-60.

-
24. Маллаев Ш.Ш. Современные особенности течения клинических вариантов ювенильного ревматоидного артрита // Межвузовского научного конгресса «Высшая школа: научные исследования» Москва, 2020. – С. 64 -65.
 25. Маллаев Ш.Ш. Обоснование хронофармакологического подхода к лечению диффузных болезни соединительной ткани у детей // Межвузовского научного конгресса «Высшая школа: научные исследования» Москва, 2020. – С. 66 -67.
 26. Маллаев Ш.Ш., Алимов А.В. Функциональное состояние надпочечников у детей с ювенильным ревматоидным артритом // Сборник статей по материалам XXXI международной научно-практической конференции № 1 (28) Москва 2020. – С.76-80.
 27. Маллаев Ш.Ш., Алимов А.В. Новые подходы к лечению ювенильного ревматоидного артрита // Сборник статей по материалам XXXI международной научно-практической конференции № 2 (62) Москва 2020. – С. 18-22.